BRPI1009346A2 - metodo de formacao de imagem optica in vivo das margens tumorais de um tumor, agente de contraste, composicao farmaceutica, e, kit - Google Patents

metodo de formacao de imagem optica in vivo das margens tumorais de um tumor, agente de contraste, composicao farmaceutica, e, kit

Info

Publication number
BRPI1009346A2
BRPI1009346A2 BRPI1009346A BRPI1009346A BRPI1009346A2 BR PI1009346 A2 BRPI1009346 A2 BR PI1009346A2 BR PI1009346 A BRPI1009346 A BR PI1009346A BR PI1009346 A BRPI1009346 A BR PI1009346A BR PI1009346 A2 BRPI1009346 A2 BR PI1009346A2
Authority
BR
Brazil
Prior art keywords
tumor
kit
optical
pharmaceutical composition
contrast agent
Prior art date
Application number
BRPI1009346A
Other languages
English (en)
Inventor
Sood Anup
Duh-Lan Lee Brian
William Castle Jason
Michael Fish Kenneth
Anne Staples Natalie
Lee Carter Randall
Original Assignee
General Eletric Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Eletric Company filed Critical General Eletric Company
Publication of BRPI1009346A2 publication Critical patent/BRPI1009346A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
BRPI1009346A 2009-03-19 2010-03-19 metodo de formacao de imagem optica in vivo das margens tumorais de um tumor, agente de contraste, composicao farmaceutica, e, kit BRPI1009346A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16153509P 2009-03-19 2009-03-19
PCT/EP2010/053619 WO2010106169A1 (en) 2009-03-19 2010-03-19 Optical imaging agents

Publications (1)

Publication Number Publication Date
BRPI1009346A2 true BRPI1009346A2 (pt) 2017-05-30

Family

ID=42331047

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1009346A BRPI1009346A2 (pt) 2009-03-19 2010-03-19 metodo de formacao de imagem optica in vivo das margens tumorais de um tumor, agente de contraste, composicao farmaceutica, e, kit

Country Status (11)

Country Link
US (1) US20120114563A1 (pt)
EP (1) EP2413976A1 (pt)
JP (1) JP2012520856A (pt)
KR (1) KR20110138246A (pt)
CN (1) CN102438659A (pt)
AU (1) AU2010224789A1 (pt)
BR (1) BRPI1009346A2 (pt)
CA (1) CA2755770A1 (pt)
MX (1) MX2011009808A (pt)
RU (1) RU2011138096A (pt)
WO (1) WO2010106169A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201015806D0 (en) 2010-09-21 2010-10-27 Ge Healthcare As Vascular imaging agents
EP3029027B1 (en) 2010-12-21 2018-06-27 Pierce Biotechnology, Inc. Fluorescent compounds
US8889884B1 (en) 2011-07-14 2014-11-18 Pierce Biotechnology, Inc. Phosphine derivatives of fluorescent compounds
US9278144B2 (en) 2011-07-29 2016-03-08 Avelas Biosciences, Inc. Selective delivery molecules and methods of use
US9249307B2 (en) 2011-08-16 2016-02-02 Pierce Biotechnology, Inc. Benzocyanine compounds
GB201116733D0 (en) 2011-09-28 2011-11-09 Ge Healthcare As Peptide margin imaging agents
US9751868B2 (en) 2012-02-28 2017-09-05 Pierce Biotechnology, Inc. Benzocyanine compounds
CN104395306B (zh) 2012-03-02 2019-04-23 皮尔斯生物科技有限公司 作为生物分子的标记染料的吲哚衍生物
JP6288970B2 (ja) * 2012-07-20 2018-03-07 キヤノン株式会社 化合物、および、前記化合物を有する光音響イメージング用造影剤
WO2014013730A1 (en) * 2012-07-20 2014-01-23 Canon Kabushiki Kaisha Compound and photoacoustic imaging contrast medium containing the compound
WO2014035712A1 (en) 2012-08-28 2014-03-06 Pierce Biotechnology, Inc. Benzopyrylium compounds
WO2014055253A1 (en) * 2012-10-04 2014-04-10 The General Hospital Corporation Methods of synthesizing and using peg-like fluorochromes
WO2014120974A1 (en) * 2013-01-30 2014-08-07 Avelas Biosciences, Inc. Selective delivery molecules and methods of use
FR3001463B1 (fr) * 2013-01-31 2015-02-20 Commissariat Energie Atomique Particules luminescentes de carbone, procede de preparation et utilisation
EP3052136A4 (en) * 2013-10-02 2017-06-21 University of Massachusetts Surface functionalized, host-guest polymer nano-assemblies and methods thereof
US9416276B2 (en) 2013-11-07 2016-08-16 Canon Kabushiki Kaisha Method for producing contrast agent
US10245329B2 (en) * 2014-09-08 2019-04-02 Canon Kabushiki Kaisha Composition having dye and conjugate of polyethyleneglycol and additive and contrast agent for photoacoustic imaging having the same
JP6652808B2 (ja) 2014-10-16 2020-02-26 キヤノン株式会社 重合体、前記重合体を有する光音響イメージング用造影剤
JP6736278B2 (ja) 2014-10-24 2020-08-05 キヤノン株式会社 重合体、前記重合体を有する光音響イメージング用造影剤
JP6700750B2 (ja) 2014-12-09 2020-05-27 キヤノン株式会社 化合物、および、前記化合物を有する光学イメージング用造影剤
WO2016097317A1 (en) * 2014-12-19 2016-06-23 Bracco Imaging Spa Intra-operative imaging
EP3242690B1 (en) * 2015-01-06 2020-09-16 De Haas, Anthony H. Near-infrared fluorescent surgical dye markers
JP2017002000A (ja) 2015-06-12 2017-01-05 キヤノン株式会社 化合物又はその薬学的に受容可能な塩、及び、前記化合物又はその薬学的に受容可能な塩を有する光音響イメージング用造影剤。
JP6789636B2 (ja) 2015-09-30 2020-11-25 キヤノン株式会社 重合体、前記重合体を有する光音響イメージング用造影剤
WO2017057653A1 (en) 2015-09-30 2017-04-06 Canon Kabushiki Kaisha Conjugate of polysarcosine and nir contrast agent for photoacoustic imaging
CN105688230B (zh) * 2016-02-02 2018-12-11 史春梦 七甲川吲哚花菁染料-聚乙二醇-叶酸复合物及制备方法和应用
CN109054013A (zh) * 2018-08-22 2018-12-21 东北大学 一种经修饰的吲哚菁绿及其制备方法
CN109738387A (zh) * 2018-12-29 2019-05-10 佛山科学技术学院 一种基于吲哚箐绿的光学相干层析成像方法和装置

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622685A (en) 1990-05-30 1997-04-22 Deutches Krebsforchunszentrum Stiftung Des Offentlichen Rechts Polyether-substituted porphyrin anti-tumor agents
DE4445065A1 (de) 1994-12-07 1996-06-13 Diagnostikforschung Inst Verfahren zur In-vivo-Diagnostik mittels NIR-Strahlung
WO1998048838A1 (en) 1997-04-29 1998-11-05 Nycomed Imaging As Compounds
GB2337523A (en) * 1998-04-29 1999-11-24 Nycomed Imaging As Light imaging contrast agents
US20100143258A1 (en) * 2008-12-05 2010-06-10 General Electric Company Tumor margin imaging agents

Also Published As

Publication number Publication date
AU2010224789A1 (en) 2011-10-06
WO2010106169A1 (en) 2010-09-23
RU2011138096A (ru) 2013-04-27
US20120114563A1 (en) 2012-05-10
JP2012520856A (ja) 2012-09-10
EP2413976A1 (en) 2012-02-08
MX2011009808A (es) 2011-09-30
CN102438659A (zh) 2012-05-02
CA2755770A1 (en) 2010-09-23
KR20110138246A (ko) 2011-12-26

Similar Documents

Publication Publication Date Title
BRPI1009346A2 (pt) metodo de formacao de imagem optica in vivo das margens tumorais de um tumor, agente de contraste, composicao farmaceutica, e, kit
BRPI0920030A2 (pt) agente de oclusão do tecido
BRPI0911656A2 (pt) formulações de nanopartículas e usos das mesmas
DK2268317T3 (da) Integrin-targeteringssubstanser og in vivo- og in vitro-billeddannelsesmetoder som anvender samme
BRPI0910760A2 (pt) método para remineralizar tecido, agente remineralizador, e, kit
BR112012008854A2 (pt) combinação, kit de combinação, uso de uma combinação, composição farmacêutica, e, método para tratar câncer em um ser humano
BRPI0908143A2 (pt) Agente de branqueamento e preparação externa da pele
BR112013009142A2 (pt) "composição modeladora de fibra queratinosa, kit modelador de fibra queratinosa e métod para tratamento de uma fibra queratinosa"
BRPI0716592A2 (pt) Composição para cuidado da pele
BRPI0719929A2 (pt) Partículas que compreendem um siloxano fluorado e métodos de preparo e uso das mesmas
BRPI0908361A2 (pt) Seringas previamente cheias contendo composição e métodos de preparação das mesmas e de estabilização de agente de ligação específico em composição.
BRPI1006733A2 (pt) kit para formação de imagem médica marcada e/ou produtos terapêuticos, agente de pré-marcação, sonda de formação de imagem, sonda terapêutica e método
BRPI0916049A2 (pt) "dispositivo para tratamento da cavidade dental e método para tratamento da cavidade dental"
EP2178442A4 (en) CATHETER FOR IMAGING IN-VIVO
DK1973466T3 (da) Ballonbilleddannelseskateter
BR112013015796A2 (pt) composição de agente de formação de imagem, método de preparar uma composição de agente de formação de imagem, método de preparar um quelante 18f-nota, e, composição farmacêutica.
ZA201006943B (en) Optical method for determining morphological parameters and physiological properties of tissue
BRPI0906576A2 (pt) Composição farmacêutica, kit, uso de um composto, e, agente terapêutico para câncer
BRPI0822885A2 (pt) Implemento para cuidado oral, método para administrar um agente ativo, e, kit para cuidado oral
BRPI0810081A2 (pt) Agente terapêutico e agente diagnóstico para doenças cerebrais de disfunção mitocondrial
BRPI0917478A8 (pt) uso de beta-lactamase bacteriana para diagnóstico in vitroe geração de imagem, diagnóstico e terapêutica in vivo
BRPI0815551A2 (pt) Tratamento através de hucbc de doença beta-amiloide
BRPI1012051A2 (pt) "composição para o cuidado oral, filme de matriz polimétrica, e métodos para preparar o filme, e para tratar uma doença ou condição da cavidade oral"
BR112012002001A2 (pt) método para tratar uma doença e/ou distúrbio do olho, formulação farmacêutica, e, kit
BR112013015798A2 (pt) composição de agente de formação de imagem, método de preparar uma composição de agente de formação de imagem, e, composição farmacêutica

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]